AMP-007 is a Phase 1/2 study for the treatment of advanced, previously treated multiple myeloma. The first phase of the study is designed to determine a safe dose of imexon that can be given to patients with advanced, previously-treated multiple myeloma. The Phase 2 part of the study is designed to provide additional safety data and to gain an understanding of whether imexon can improve the outcome for patients with multiple myeloma

Inclusion Criteria:

• Advanced myeloma, with measurable disease as defined in the protocol.
• Prior treatment, at least 2 prior regimens are required. This may include prior treatment with investigational products.
• Able to perform the activities of daily living.
• Off prior therapy for at least 2-4 weeks depending on the drug.
• Blood counts and blood chemistries in or near normal range.
• If female, neither pregnant nor nursing.
• Willing to use contraceptives to prevent pregnancy.
• No other serious illnesses.
• No other active malignancy.
• No serious infections.
• No current other drug therapy for the myeloma except for steroid therapy under certain circumstances. Biphosphonate therapy is permitted.
• Prior radiation is permitted.

Exclusion Criteria:

• Use of corticosteroids for amyloid disorders, or high dose chronic steroids.